Novartis AG
NVSEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $240,675 | $233,760 | $216,421 | $190,951 |
| - Cash | $9,556 | $6,656 | $7,062 | $11,459 |
| + Debt | $32,022 | $32,637 | $31,270 | $31,258 |
| Enterprise Value | $263,141 | $259,741 | $240,629 | $210,750 |
| Revenue | $14,358 | $14,836 | $13,620 | $13,558 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Gross Profit | $10,819 | $11,514 | $10,393 | $10,234 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| EBITDA | $5,841 | $6,076 | $5,831 | $5,188 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |
| Net Income | $3,928 | $4,041 | $3,662 | $2,818 |
| % Margin | 27.4% | 27.2% | 26.9% | 20.8% |
| EPS Diluted | 2 | 2.06 | 1.82 | 1.41 |
| % Growth | -2.9% | 13.2% | 29.1% | – |
| Operating Cash Flow | $6,571 | $6,664 | $3,645 | $4,193 |
| Capital Expenditures | -$831 | -$558 | -$254 | -$1,131 |
| Free Cash Flow | $5,740 | $6,106 | $3,391 | $3,062 |